Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. leukemia 
3. original article 
4. article
Show authors
•  Original Article
•  Published: 25 October 2013


Myeloma
Continued improvement in
survival in multiple myeloma:
changes in early mortality and
outcomes in older patients
•  S K Kumar
1,
•  A Dispenzieri1,
•  M Q Lacy1,
•  M A Gertz1,
•  F K Buadi1,
•  S Pandey2,
•  P Kapoor1,
•  D Dingli1,
•  S R Hayman1,
•  N Leung1,3,
•  J Lust1,
•  A McCurdy1,
•  S J Russell1,
•  S R Zeldenrust1,
•  R A Kyle1 &
•  …
•  S V Rajkumar1 
Leukemia volume 28, pages 1122–1128 (2014)Cite this article
•  11k Accesses
•  1250 Citations
•  79 Altmetric
•  Metrics details
Subjects


•  Drug therapy
•  Geriatrics
•  Myeloma
Abstract
Therapy for multiple myeloma (MM) has markedly changed in the
past decade with the introduction of new drugs, but it is not clear
whether the improvements have been sustained. We studied 1038
patients diagnosed between 2001 and 2010, grouping patients into
two 5-year periods by diagnosis, 2001–2005 and 2006–2010. The
median estimated follow-up for the cohort was 5.9 years with 47%
alive at the last follow-up. The median overall survival (OS) for the
entire cohort was 5.2 years: 4.6 years for patients in the 2001–2005
group compared with 6.1 years for the 2006–2010 cohort
(P=0.002). The improvement was primarily seen among patients
over 65 years, the 6-year OS improving from 31 to 56%, P<0.001.
Only 10% of patients died during the first year in the latter group,
compared with 16% in the earlier cohort (P<0.01), suggesting
improvement in early mortality. The improved outcomes were
linked closely to the use of one or more new agents in initial
therapy. The current results confirm continued survival
improvement in MM and highlight the impact of initial therapy
with novel agents. Most importantly, we demonstrate that the
improved survival is benefitting older patients and that early
mortality in this disease has reduced considerably.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Subscribe to this journal


Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs
•  Contact customer support
Figure 1
[image]
Figure 2
[image]
Figure 3
[image]
Similar content being viewed by others
[image]
Mortality trends in multiple myeloma after the
introduction of novel therapies in the United States
Article 26 October 2021


[image]
Attrition rates and treatment outcomes in multiple
myeloma: real-world data over a 40-year period
Article Open access 26 May 2025
[image]
Decrease in early mortality for newly diagnosed
multiple myeloma patients in the Netherlands: a
population-based study
Article Open access 11 November 2021
References
1. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman
SR et al. Management of newly diagnosed symptomatic
multiple myeloma: updated Mayo Stratification of Myeloma
and Risk-Adapted Therapy (mSMART) consensus guidelines
2013. Mayo Clin Proc 2013; 88: 360–376.
Article  PubMed  Google Scholar 
2. Anderson KC . The 39th David A. Karnofsky Lecture: bench-
to-bedside translation of targeted therapies in multiple
myeloma. J Clin Oncol 2012; 30: 445–452.
Article  CAS  PubMed  Google Scholar 
3. Kyle RA . Targeted therapy of multiple myeloma. Hematology
2012; 17 (Suppl 1): S125–S128.
Article  CAS  PubMed  Google Scholar 
4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman
SR, Buadi FK et al. Improved survival in multiple myeloma
and the impact of novel therapies. Blood 2008; 111: 2516–
2520.


Article  CAS  PubMed  PubMed Central  Google Scholar 
5. Brenner H, Gondos A, Pulte D . Recent major improvement in
long-term survival of younger patients with multiple
myeloma. Blood 2008; 111: 2521–2526.
Article  CAS  PubMed  Google Scholar 
6. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N,
Haessler J et al. Combining fluorescent in situ hybridization
data with ISS staging improves risk assessment in myeloma:
an International Myeloma Working Group collaborative
project. Leukemia 2013; 27: 711–717.
Article  CAS  PubMed  Google Scholar 
7. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ,
Gertz MA et al. Trisomies in multiple myeloma: impact on
survival in patients with high-risk cytogenetics. Blood 2012;
119: 2100–2105.
Article  CAS  PubMed  PubMed Central  Google Scholar 
8. Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH,
van der Holt B et al. A gene expression signature for high-risk
multiple myeloma. Leukemia 2012; 26: 2406–2413.
Article  CAS  PubMed  Google Scholar 
9. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD Jr, Bryant B .
High-risk myeloma: a gene expression-based risk-stratification
model for newly diagnosed multiple myeloma treated with
high-dose therapy is predictive of outcome in relapsed disease
treated with single-agent bortezomib or high-dose
dexamethasone. Blood 2008; 111: 968–969.
Article  CAS  PubMed  PubMed Central  Google Scholar 
10. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W,
Jezequel P et al. Prediction of survival in multiple myeloma
based on gene expression profiles reveals cell cycle and
chromosomal instability signatures in high-risk patients and


hyperdiploid signatures in low-risk patients: a study of the
Intergroupe Francophone du Myelome. J Clin Oncol 2008; 26:
4798–4805.
Article  CAS  PubMed  Google Scholar 
11. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath
S, Irwin D et al. A phase 2 study of bortezomib in relapsed,
refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
Article  CAS  PubMed  Google Scholar 
12. Richardson PG, Sonneveld P, Schuster MW, Irwin D,
Stadtmauer EA, Facon T et al. Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Engl J Med
2005; 352: 2487–2498.
Article  CAS  PubMed  Google Scholar 
13. Weber DM, Chen C, Niesvizky R, Wang M, Belch A,
Stadtmauer EA et al. Lenalidomide plus dexamethasone for
relapsed multiple myeloma in North America. N Engl J Med
2007; 357: 2133–2142.
CAS  PubMed  Google Scholar 
14. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau
JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for
relapsed or refractory multiple myeloma. N Engl J Med 2007;
357: 2123–2132.
Article  CAS  PubMed  Google Scholar 
15. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR .
Phase III clinical trial of thalidomide plus dexamethasone
compared with dexamethasone alone in newly diagnosed
multiple myeloma: a clinical trial coordinated by the Eastern
Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–
436.
Article  CAS  PubMed  Google Scholar 


16. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R .
Thalidomide alone or with dexamethasone for previously
untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19.
Article  CAS  PubMed  Google Scholar 
17. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S
et al. A phase 2 study of single-agent carfilzomib
(PX-171-003-A1) in patients with relapsed and refractory
multiple myeloma. Blood 2012; 120: 2817–2825.
Article  CAS  PubMed  PubMed Central  Google Scholar 
18. Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M et
al. Pomalidomide plus low-dose dexamethasone versus high-
dose dexamethasone alone for patients with relapsed and
refractory multiple myeloma (MM-003): a randomised, open-
label, phase 3 trial. Lancet Oncol 2013; 14: 1055–1066.
Article  CAS  PubMed  Google Scholar 
19. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA
et al. Clinical and biologic implications of recurrent genomic
aberrations in myeloma. Blood 2003; 101: 4569–4575.
Article  CAS  PubMed  Google Scholar 
20. Greipp PR, Kumar S . Plasma cell labeling index. Methods Mol
Med 2005; 113: 25–35.
PubMed  Google Scholar 
21. Kaplan E, Meier P . Nonparametric estimation from
incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Article  Google Scholar 
22. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F,
Hulin C et al. Genetic abnormalities and survival in multiple
myeloma: the experience of the Intergroupe Francophone du
Myelome. Blood 2007; 109: 3489–3495.


Article  CAS  PubMed  Google Scholar 
23. Jagannath S, Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA et al. Bortezomib appears to
overcome the poor prognosis conferred by chromosome 13
deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151–157.
Article  CAS  PubMed  Google Scholar 
24. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van
der Holt B et al. Administration of bortezomib before and
after autologous stem cell transplantation improves outcome
in multiple myeloma patients with deletion 17p. Blood 2012;
119: 940–948.
Article  CAS  PubMed  Google Scholar 
25. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R,
Wittebol S, Sinnige H et al. Phase III study of the value of
thalidomide added to melphalan plus prednisone in elderly
patients with newly diagnosed multiple myeloma: the
HOVON 49 Study. J Clin Oncol 2010; 28: 3160–3166.
Article  CAS  PubMed  Google Scholar 
26. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen
C et al. Efficacy of melphalan and prednisone plus
thalidomide in patients older than 75 years with newly
diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol
2009; 27: 3664–3670.
Article  CAS  PubMed  Google Scholar 
27. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie
B et al. Melphalan and prednisone plus thalidomide versus
melphalan and prednisone alone or reduced-intensity
autologous stem cell transplantation in elderly patients with
multiple myeloma (IFM 99-06): a randomised trial. Lancet
2007; 370: 1209–1218.
Article  CAS  PubMed  Google Scholar 


28. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V,
Callea V et al. Oral melphalan and prednisone chemotherapy
plus thalidomide compared with melphalan and prednisone
alone in elderly patients with multiple myeloma: randomised
controlled trial. Lancet 2006; 367: 825–831.
Article  CAS  PubMed  Google Scholar 
29. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA,
Shpilberg O, Kropff M et al. Bortezomib plus melphalan and
prednisone for initial treatment of multiple myeloma. N Engl J
Med 2008; 359: 906–917.
Article  CAS  PubMed  Google Scholar 
30. Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR,
Dingli D et al. Early versus delayed autologous transplantation
after immunomodulatory agents-based induction therapy in
patients with newly diagnosed multiple myeloma. Cancer
2012; 118: 1585–1592.
Article  PubMed  Google Scholar 
31. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR,
Buadi FK et al. Autologous stem cell transplantation in
patients of 70 years and older with multiple myeloma: results
from a matched pair analysis. Am J Hematol 2008; 83: 614–
617.
Article  PubMed  Google Scholar 
32. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S,
Pandha H et al. The role of autologous transplantation in
patients with multiple myeloma aged 65 years and over. Bone
Marrow Transplant 2000; 25: 533–539.
Article  CAS  PubMed  Google Scholar 
33. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F,
Morgan G et al. Early mortality after diagnosis of multiple
myeloma: analysis of patients entered onto the United
kingdom Medical Research Council trials between 1980 and


2002-Medical Research Council Adult Leukaemia Working
Party. J Clin Oncol 2005; 23: 9219–9226.
Article  PubMed  Google Scholar 
34. Moreau P, Planche L, Attal M, Hulin C, Facon T, Caillot D et
al. The combination of ISS 3, high LDH and t(4;14) and/or
Del(17p) identify a simple prognostic index for overall
survival in patients treated with novel agents-based induction
therapy and front-line autologous stem cell transplantation,
and allow the definition of a subgroup of patients at high-risk
of early death from progressive disease. ASH Ann Meeting
Abstr 2012; 120: 598.
Google Scholar 
35. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B,
Blade J et al. International staging system for multiple
myeloma. J Clin Oncol 2005; 23: 3412–3420.
Article  PubMed  Google Scholar 
36. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R . High
serum lactate dehydrogenase level as a marker for drug
resistance and short survival in multiple myeloma. Ann Intern
Med 1991; 115: 931–935.
Article  CAS  PubMed  Google Scholar 
37. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E,
Delimpasi S et al. High serum lactate dehydrogenase adds
prognostic value to the international myeloma staging system
even in the era of novel agents. Eur J Haematol 2010; 85:
114–119.
PubMed  Google Scholar 
38. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE,
Kyle RA . Plasma cell labeling index and beta 2-microglobulin
predict survival independent of thymidine kinase and C-
reactive protein in multiple myeloma. Blood 1993; 81: 3382–
3387.


CAS  PubMed  Google Scholar 
39. Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri
A, Lacy MQ et al. Efficacy of thalidomide- or lenalidomide-
based therapy in proliferative multiple myeloma. Leukemia
2011; 25: 1195–1197.
Article  CAS  PubMed  Google Scholar 
40. Hose D, Reme T, Hielscher T, Moreaux J, Messner T,
Seckinger A et al. Proliferation is a central independent
prognostic factor and target for personalized and risk-adapted
treatment in multiple myeloma. Haematologica 2011; 96: 87–
95.
Article  PubMed  Google Scholar 
Download references
Acknowledgements
This work was supported in part by the Mayo Clinic Hematological
Malignancies Program and Paul Calabresi K12 Award (Grant No.
CA90628), by Grants CA168762, CA07476, CA62242, CA100707
and CA83724 from the National Cancer Institute, and by the Jabbs
Foundation and the Henry J. Predolin Foundation.
Author contributions
SKK was involved in design of concept, data collection, analysis and
writing the paper. AD, MQL, SRH, SRZ, FKB, NL, RAK, SVR, SP, PK,
DD, SJR, JL, AM and MAG were involved in writing the manuscript.
Author information
Authors and Affiliations
1. Division of Hematology, Mayo Clinic, Rochester, MN, USA


S K Kumar, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, P
Kapoor, D Dingli, S R Hayman, N Leung, J Lust, A McCurdy, S
J Russell, S R Zeldenrust, R A Kyle & S V Rajkumar
2. Division of Nephrology, Mayo Clinic, Rochester, MN, USA
S Pandey
3. Department of Internal Medicine, Mayo Clinic, Rochester,
MN, USA
N Leung
Authors
1. S K Kumar
View author publications
Search author on:PubMed Google Scholar
2. A Dispenzieri
View author publications
Search author on:PubMed Google Scholar
3. M Q Lacy
View author publications
Search author on:PubMed Google Scholar
4. M A Gertz
View author publications
Search author on:PubMed Google Scholar
5. F K Buadi
View author publications
Search author on:PubMed Google Scholar
6. S Pandey
View author publications


Search author on:PubMed Google Scholar
7. P Kapoor
View author publications
Search author on:PubMed Google Scholar
8. D Dingli
View author publications
Search author on:PubMed Google Scholar
9. S R Hayman
View author publications
Search author on:PubMed Google Scholar
10. N Leung
View author publications
Search author on:PubMed Google Scholar
11. J Lust
View author publications
Search author on:PubMed Google Scholar
12. A McCurdy
View author publications
Search author on:PubMed Google Scholar
13. S J Russell
View author publications
Search author on:PubMed Google Scholar
14. S R Zeldenrust
View author publications
Search author on:PubMed Google Scholar
15. R A Kyle


View author publications
Search author on:PubMed Google Scholar
16. S V Rajkumar
View author publications
Search author on:PubMed Google Scholar
Corresponding author
Correspondence to S K Kumar.
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the
Leukemia website
Supplementary information
Supplementary Figure 1A (JPG 37 kb)
Supplementary Figure 1B (JPG 38 kb)
Supplementary Figure 2A (JPG 35 kb)
Supplementary Figure 2B (JPG 35 kb)


Supplementary Figure 2C (JPG 38 kb)
Supplementary Figure 2D (JPG 38 kb)
Supplementary Figure 3A (JPG 37 kb)
Supplementary Figure 3B (JPG 36 kb)
Supplementary Figure 3C (JPG 37 kb)
Supplementary Figure 3D (JPG 36 kb)
Supplementary Figures Legend (DOC 399 kb)
Rights and permissions
Reprints and permissions
About this article
Cite this article
Kumar, S., Dispenzieri, A., Lacy, M. et al. Continued improvement in
survival in multiple myeloma: changes in early mortality and
outcomes in older patients. Leukemia 28, 1122–1128 (2014).
https://doi.org/10.1038/leu.2013.313
Download citation
•  Received: 01 October 2013
•  Accepted: 15 October 2013
•  Published: 25 October 2013
•  Issue date: May 2014


•  DOI: https://doi.org/10.1038/leu.2013.313
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
Keywords
•  immunomodulatory
•  multiple myeloma
•  proteasome inhibitors
•  survival
This article is cited by
•  Fc receptor-like 5 (FCRL5)-directed CAR-T cells
exhibit antitumor activity against multiple
myeloma
○  Zhengyu Yu
○  Hexian Li
○  Ting Niu
Signal Transduction and Targeted Therapy (2024)
•  Personalized Treatment of Multiple Myeloma in
Frail Patients
○  Jodi J. Lipof


○  Nadine Abdallah
○  Brea Lipe
Current Oncology Reports (2024)
•  Excellent long-term pain response and local
control following postoperative radiotherapy in
patients with multiple myeloma
○  Justus Kaufmann
○  Annika Ute Täubl
○  Tilman Bostel
Strahlentherapie und Onkologie (2024)
•  Primary analysis of a prospective cohort study of
Japanese patients with plasma cell neoplasms in
the novel drug era (2016–2021)
○  Hirohiko Shibayama
○  Mitsuhiro Itagaki
○  Shinsuke Iida
International Journal of Hematology (2024)
•  Large-scale real-life analysis of survival and
usage of therapies in multiple myeloma
○  N. Lopez-Muñoz
○  G. Hernández-Ibarburu
○  J. Martinez-Lopez
Journal of Hematology & Oncology (2023)
 Access through your institution
Buy or subscribe
Advertisement
[image]


Explore content
•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Current issue
•  Collections
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Information
•  Open access publishing
•  About the Editors
•  Contact
•  Supplements
•  For Advertisers
•  Subscribe
Publish with us
•  For Authors & Referees
•  Language editing services
•  Open access funding
•  Submit manuscript
Search


Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Leukemia (Leukemia)
ISSN 1476-5551 (online)
ISSN 0887-6924 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access


Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies


•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


[image]


